Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer.

PubWeight™: 4.19‹?› | Rank: Top 1%

🔗 View Article (PMID 17135639)

Published in J Clin Oncol on December 01, 2006

Authors

Stephen E Jones1, Michael A Savin, Frankie Ann Holmes, Joyce A O'Shaughnessy, Joanne L Blum, Svetislava Vukelja, Kristi J McIntyre, John E Pippen, James H Bordelon, Robert Kirby, John Sandbach, William J Hyman, Pankaj Khandelwal, Angel G Negron, Donald A Richards, Stephen P Anthony, Robert G Mennel, Kristi A Boehm, Walter G Meyer, Lina Asmar

Author Affiliations

1: US Oncology Research, Inc, Texas Oncology, Dallas, TX 75246, USA. steve.jones@usoncology.com

Associated clinical trials:

Neoadjuvant Treatment of Docetaxel, Anthracycline and Cyclophosphamide (TAC) Versus Docetaxel and Cyclophosphamide (TC) in Triple-Negative or Her2 Positive Breast Cancer (NATT) | NCT00912444

Explore the Individual Treatment of Docetaxel and Paclitaxel in NSCLC, NPC and BRC by PK-guided Dosing Strategy | NCT01891123

Study of CYP2C19 and ALDH3A1 Polymorphisms in Breast Cancer Patients | NCT04581967

Articles citing this

Neuropathy is not associated with clinical outcomes in patients receiving adjuvant taxane-containing therapy for operable breast cancer. J Clin Oncol (2012) 1.85

Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy. J Clin Oncol (2013) 1.81

Risk of hospitalization according to chemotherapy regimen in early-stage breast cancer. J Clin Oncol (2014) 1.62

Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197. J Clin Oncol (2008) 1.60

Decline in the use of anthracyclines for breast cancer. J Clin Oncol (2012) 1.51

Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring. Br J Cancer (2009) 1.38

Taxanes: optimizing adjuvant chemotherapy for early-stage breast cancer. Nat Rev Clin Oncol (2009) 1.34

Systemic treatment strategies for triple-negative breast cancer. World J Clin Oncol (2014) 1.25

Recent advances in systemic therapy: advances in adjuvant systemic chemotherapy of early breast cancer. Breast Cancer Res (2009) 1.09

Febrile neutropenia rates with adjuvant docetaxel and cyclophosphamide chemotherapy in early breast cancer: discrepancy between published reports and community practice-a retrospective analysis. Curr Oncol (2010) 1.09

Impact of colony-stimulating factors to reduce febrile neutropenic events in breast cancer patients receiving docetaxel plus cyclophosphamide chemotherapy. Support Care Cancer (2010) 1.07

Hepatitis B virus reactivation risk varies with different chemotherapy regimens commonly used in solid tumours. Br J Cancer (2013) 1.04

Matters of the heart: cardiac toxicity of adjuvant systemic therapy for early-stage breast cancer. Curr Oncol (2008) 1.00

Incidence of taxane-induced pain and distress in patients receiving chemotherapy for early-stage breast cancer: a retrospective, outcomes-based survey. Curr Oncol (2010) 0.99

Topoisomerase II{alpha} amplification does not predict benefit from dose-intense cyclophosphamide, doxorubicin, and fluorouracil therapy in HER2-amplified early breast cancer: results of CALGB 8541/150013. J Clin Oncol (2009) 0.98

Early breast cancer in the older woman. Oncologist (2011) 0.97

The German SUCCESS C Study - The First European Lifestyle Study on Breast Cancer. Breast Care (Basel) (2010) 0.97

Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+/HER2- breast cancer patients: results from the GEICAM 9906 trial. Breast Cancer Res (2014) 0.95

Delayed emotional recovery after taxane-based chemotherapy. Cancer (2008) 0.93

Canadian supportive care recommendations for the management of neutropenia in patients with cancer. Curr Oncol (2008) 0.93

Phase III placebo-controlled, double-blind, randomized trial of pegfilgrastim to reduce the risk of febrile neutropenia in breast cancer patients receiving docetaxel/cyclophosphamide chemotherapy. Support Care Cancer (2015) 0.92

Primary G-CSF prophylaxis for adjuvant TC or FEC-D chemotherapy outside of clinical trial settings: a systematic review and meta-analysis. Support Care Cancer (2012) 0.92

Relationship between Topoisomerase 2A RNA Expression and Recurrence after Adjuvant Chemotherapy for Breast Cancer. Clin Cancer Res (2009) 0.90

Docetaxel and bortezomib downregulate Bcl-2 and sensitize PC-3-Bcl-2 expressing prostate cancer cells to irradiation. World J Urol (2008) 0.89

Benefit risk assessment and update on the use of docetaxel in the management of breast cancer. Cancer Manag Res (2013) 0.88

Primary systemic therapy with intermittent weekly paclitaxel plus gemcitabine in patients with stage II and III breast cancer: a phase II trial. Invest New Drugs (2009) 0.86

Adjuvant chemotherapy, with or without taxanes, in early or operable breast cancer: a meta-analysis of 19 randomized trials with 30698 patients. PLoS One (2011) 0.86

A randomised pilot Phase II study of doxorubicin and cyclophosphamide (AC) or epirubicin and cyclophosphamide (EC) given 2 weekly with pegfilgrastim (accelerated) vs 3 weekly (standard) for women with early breast cancer. Br J Cancer (2009) 0.86

The cost-utility of adjuvant chemotherapy using docetaxel and cyclophosphamide compared with doxorubicin and cyclophosphamide in breast cancer. Curr Oncol (2011) 0.86

Extracellularly secreted APE1/Ref-1 triggers apoptosis in triple-negative breast cancer cells via RAGE binding, which is mediated through acetylation. Oncotarget (2015) 0.85

Optimisation of steroid prophylaxis schedules in breast cancer patients receiving docetaxel chemotherapy-a survey of health care providers and patients. Support Care Cancer (2015) 0.85

Second non-breast primary cancer following adjuvant therapy for early breast cancer: a report from the International Breast Cancer Study Group. Eur J Cancer (2008) 0.84

Presentation and management of docetaxel-related adverse effects in patients with breast cancer. Cancer Manag Res (2014) 0.83

The triterpenoid cucurbitacin B augments the antiproliferative activity of chemotherapy in human breast cancer. Int J Cancer (2012) 0.82

Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node-positive breast cancer: the 8-year follow-up results of the UNICANCER-PACS01 trial. Oncologist (2012) 0.82

Pharmacogenomics as a risk mitigation strategy for chemotherapeutic cardiotoxicity. Pharmacogenomics (2013) 0.82

Taxane acute pain syndrome (TAPS) in patients receiving taxane-based chemotherapy for breast cancer-a systematic review. Support Care Cancer (2016) 0.80

17α-ethynyl-5α-androstane-3α, 17β-diol treatment of MNU-induced mammary cancer in rats. Int J Breast Cancer (2011) 0.80

A modified filgrastim regimen does not reduce pain burden compared to pegfilgrastim in women receiving chemotherapy for non-metastatic breast cancer. Support Care Cancer (2014) 0.79

Docetaxel for the post-surgery treatment of patients with node-positive breast cancer. Ther Clin Risk Manag (2008) 0.79

A Randomized Phase II Trial of Capecitabine Plus Vinorelbine Followed by Docetaxel Versus Adriamycin Plus Cyclophosphamide Followed by Docetaxel as Neoadjuvant Chemotherapy for Breast Cancer. Cancer Res Treat (2014) 0.79

A nomogram for predicting pathological complete response in patients with human epidermal growth factor receptor 2 negative breast cancer. BMC Cancer (2016) 0.78

Mammography Screening and Treatment of Breast Cancer in the Elderly. Breast Care (Basel) (2008) 0.78

Adjuvant Metronomic CMF in a Contemporary Breast Cancer Cohort: What's Old Is New. Clin Breast Cancer (2015) 0.78

Anthracycline regimen adherence in older patients with early breast cancer. Oncologist (2012) 0.78

The potential role of nanotechnology in therapeutic approaches for triple negative breast cancer. Pharmaceutics (2013) 0.78

Risk of febrile neutropenia in patients receiving emerging chemotherapy regimens. Support Care Cancer (2014) 0.78

Adjuvant Systemic Therapy in Older Breast Cancer Women: Can We Optimize the Level of Care? Cancers (Basel) (2015) 0.78

Incidence of febrile neutropenia during adjuvant chemotherapy for breast cancer: a prospective study. Curr Oncol (2012) 0.78

The impact of adjuvant chemotherapy in older breast cancer patients on clinical and biological aging parameters. Oncotarget (2016) 0.78

Guideline-Based Peer-to-Peer Consultation Optimizes Pegfilgrastim Use With No Adverse Clinical Consequences. J Oncol Pract (2012) 0.78

Filling in the gaps: reporting of concurrent supportive care therapies in breast cancer chemotherapy trials. Support Care Cancer (2011) 0.77

Breast cancer (non-metastatic). BMJ Clin Evid (2011) 0.77

UFT (tegafur and uracil) as postoperative adjuvant chemotherapy for solid tumors (carcinoma of the lung, stomach, colon/rectum, and breast): clinical evidence, mechanism of action, and future direction. Surg Today (2007) 0.76

Breast cancer follow-up strategies in randomized phase III adjuvant clinical trials: a systematic review. J Exp Clin Cancer Res (2013) 0.76

Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology). J Clin Oncol (2017) 0.75

Update of evidence in chemotherapy for breast cancer. Int J Clin Oncol (2008) 0.75

Comparison of the Control of Nausea and Vomiting among Several Moderately Emetic-Risk Chemotherapy Regimens. J Cancer (2016) 0.75

Clinical utility of aromatase inhibitors as adjuvant treatment in postmenopausal early breast cancer. Clin Med Insights Womens Health (2013) 0.75

Febrile neutropenia rates with adjuvant docetaxel and cyclophosphamide chemotherapy in early breast cancer: discrepancy between published reports and community practice-an updated analysis. Curr Oncol (2012) 0.75

Senior adult oncology: three cases of advanced cancer in patients of advanced age. Semin Oncol (2012) 0.75

Breast cancer (non-metastatic). BMJ Clin Evid (2007) 0.75

HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician's choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer. BMC Cancer (2016) 0.75

Avoiding the use of anthracyclines in the adjuvant therapy of breast cancer: the "TC" (docetaxel and cyclophosphamide) regimen. Curr Oncol Rep (2008) 0.75

How transferable are recommendations of the era of treating conventionally defined breast cancer for the era of molecularly characterised breast cancer? Gland Surg (2012) 0.75

Changes in ovarian function in premenopausal women with breast cancer undergoing adjuvant TC (docetaxel and cyclophosphamide) chemotherapy during a brief period of amenorrhea around the last chemotherapy cycle. Springerplus (2014) 0.75

The impact of chemotherapy dose intensity and supportive care on the risk of febrile neutropenia in patients with early stage breast cancer: a prospective cohort study. Springerplus (2015) 0.75

Pharmacokinetics and safety of cyclophosphamide and docetaxel in a hemodialysis patient with early stage breast cancer: a case report. BMC Cancer (2015) 0.75

Phase II study of adjuvant docetaxel and carboplatin with/without doxorubicin and cyclophosphamide in triple negative breast cancer: a randomised controlled clinical trial. Contemp Oncol (Pozn) (2017) 0.75

Optimal approach in early breast cancer: Adjuvant and neoadjuvant treatment. EJC Suppl (2013) 0.75

A Canadian economic analysis of U.S. Oncology Adjuvant Trial 9735. Curr Oncol (2011) 0.75

Safety Results of Docetaxel-(Taxotere®)-Based Chemotherapy in Early Breast Cancer Patients of Asia-Pacific Region: Asia-Pacific Breast Initiative II. J Breast Cancer (2015) 0.75

Bendamustine in Metastatic Breast Cancer: An Old Drug in New Design. Breast Care (Basel) (2008) 0.75

The role of HER-2 in Breast Cancer. J Surg Sci (2014) 0.75

Node-positive Breast Cancer: Which Are the Best Chemotherapy Regimens? Breast Care (Basel) (2008) 0.75

Safety and tolerability of docetaxel, cyclophosphamide, and trastuzumab compared to standard trastuzumab-based chemotherapy regimens for early-stage human epidermal growth factor receptor 2-positive breast cancer. J Breast Cancer (2014) 0.75

Variation in type of adjuvant chemotherapy received among patients with stage I breast cancer: A multi-institutional study. Cancer (2015) 0.75

The JACS prospective cohort study of newly diagnosed women with breast cancer investigating joint and muscle pain, aches, and stiffness: pain and quality of life after primary surgery and before adjuvant treatment. BMC Cancer (2014) 0.75

Multicenter Phase II Study with Weekly Bendamustine and Paclitaxel as First- or Later-Line Therapy in Patients with Metastatic Breast Cancer: RiTa II Trial. Breast Care (Basel) (2011) 0.75

Feasibility of 4 cycles of docetaxel and cyclophosphamide every 14 days as an adjuvant regimen for breast cancer: a Wisconsin Oncology Network study. Clin Breast Cancer (2013) 0.75

Docetaxel plus cyclophosphamide in adjuvant breast cancer. J Clin Oncol (2007) 0.75

Prevention and Treatment of Bone Metastases in Breast Cancer. J Clin Med (2013) 0.75

A phase I study of combination therapy with nanoparticle albumin-bound paclitaxel and cyclophosphamide in patients with metastatic or recurrent breast cancer. Int J Clin Oncol (2014) 0.75

Impact of an electronic tool in prescribing primary prophylaxis with ciprofloxacin or granulocyte colony-stimulating factor for breast cancer patients receiving TC chemotherapy. Support Care Cancer (2016) 0.75

Articles by these authors

Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA (2010) 8.93

Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers. J Clin Oncol (2010) 6.34

A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. Nat Genet (2010) 4.96

Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol (2010) 4.94

Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med (2011) 4.94

Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet (2011) 4.73

Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol (2010) 4.62

Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735. J Clin Oncol (2009) 4.56

Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol (2002) 4.47

Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol (2008) 3.54

Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Am J Hum Genet (2008) 3.41

Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res (2009) 2.90

Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study. Lancet Oncol (2007) 2.90

Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial. Lancet (2011) 2.88

Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol (2006) 2.85

Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study. J Clin Oncol (2012) 2.75

The global breast cancer burden: variations in epidemiology and survival. Clin Breast Cancer (2005) 2.69

Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer. J Clin Oncol (2009) 2.13

Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol (2009) 2.05

Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine. J Clin Oncol (2010) 2.03

Evolutionary pathways in BRCA1-associated breast tumors. Cancer Discov (2012) 2.01

Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: a combined review of cardiac data from the National Surgical Adjuvant breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 clinical trials. J Clin Oncol (2010) 1.98

Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer. J Clin Oncol (2004) 1.82

PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. J Clin Oncol (2013) 1.81

Oophorectomy after menopause and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev (2012) 1.78

Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer. J Urol (2002) 1.77

Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor. N Engl J Med (2015) 1.75

Genome and transcriptome sequencing in prospective metastatic triple-negative breast cancer uncovers therapeutic vulnerabilities. Mol Cancer Ther (2012) 1.72

Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes. Clin Breast Cancer (2007) 1.66

Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: a single-group, open-label, phase 2 study. Lancet Oncol (2013) 1.61

Breast cancer chemoprevention phase I evaluation of biomarker modulation by arzoxifene, a third generation selective estrogen receptor modulator. Clin Cancer Res (2004) 1.58

Phase III multicenter trial of doxorubicin plus cyclophosphamide followed by paclitaxel compared with doxorubicin plus paclitaxel followed by weekly paclitaxel as adjuvant therapy for women with high-risk breast cancer. J Clin Oncol (2010) 1.56

The addition of hormone therapy to tamoxifen does not prevent hot flashes in women at high risk for developing breast cancer. Breast Cancer Res Treat (2009) 1.41

Results of a phase 2 study of bortezomib in patients with relapsed or refractory indolent lymphoma. Blood (2009) 1.26

Gemcitabine, Cisplatin, and sunitinib for metastatic urothelial carcinoma and as preoperative therapy for muscle-invasive bladder cancer. Clin Genitourin Cancer (2012) 1.22

Radiation microsphere-induced GI ulcers after selective internal radiation therapy for hepatic tumors: an underrecognized clinical entity. Gastrointest Endosc (2009) 1.20

Molecular profiling of human mammary gland links breast cancer risk to a p27(+) cell population with progenitor characteristics. Cell Stem Cell (2013) 1.14

Pharmacogenomics of tamoxifen in a nutshell-and who broke the nutcracker? J Oncol Pract (2005) 1.12

Molecular signatures predict outcomes of breast cancer. N Engl J Med (2006) 1.12

Cancer of the pancreas: are we making progress? A review of studies in the US Oncology Research Network. Cancer Control (2008) 1.10

Comparison of menopausal symptoms during the first year of adjuvant therapy with either exemestane or tamoxifen in early breast cancer: report of a Tamoxifen Exemestane Adjuvant Multicenter trial substudy. J Clin Oncol (2007) 1.08

A pilot study utilizing multi-omic molecular profiling to find potential targets and select individualized treatments for patients with previously treated metastatic breast cancer. Breast Cancer Res Treat (2014) 1.08

Phase II study of trastuzumab plus gemcitabine in chemotherapy-pretreated patients with metastatic breast cancer. Clin Breast Cancer (2004) 1.07

Phase III trial of cetuximab, bevacizumab, and 5-fluorouracil/leucovorin vs. FOLFOX-bevacizumab in colorectal cancer. Clin Colorectal Cancer (2011) 1.07

Modification of BRCA1-Associated Breast and Ovarian Cancer Risk by BRCA1-Interacting Genes. Cancer Res (2011) 1.05

Particle systems for efficient and accurate high-order finite element visualization. IEEE Trans Vis Comput Graph (2007) 1.04

Genetic variation in insulin-like growth factor signaling genes and breast cancer risk among BRCA1 and BRCA2 carriers. Breast Cancer Res (2009) 1.04

Phase II trial of capecitabine and weekly paclitaxel as first-line therapy for metastatic breast cancer. J Clin Oncol (2006) 1.03

Cardiac toxicity of trastuzumab-related regimens in HER2-overexpressing breast cancer. Clin Breast Cancer (2007) 1.03

Bilateral prophylactic oophorectomy and bilateral prophylactic mastectomy in a prospective cohort of unaffected BRCA1 and BRCA2 mutation carriers. Clin Breast Cancer (2007) 1.01

Modification of ovarian cancer risk by BRCA1/2-interacting genes in a multicenter cohort of BRCA1/2 mutation carriers. Cancer Res (2009) 1.01

Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m(2) every 21 days in patients with cancer. Invest New Drugs (2012) 1.01

Phase II evaluation of nanoparticle albumin-bound paclitaxel in platinum-sensitive patients with recurrent ovarian, peritoneal, or fallopian tube cancer. J Clin Oncol (2009) 1.00

Phase II multicenter trial of a weekly paclitaxel and carboplatin regimen in patients with advanced breast cancer. J Clin Oncol (2002) 1.00

Randomized placebo-controlled phase II trial of perifosine plus capecitabine as second- or third-line therapy in patients with metastatic colorectal cancer. J Clin Oncol (2011) 0.99

Phase II trial of nanoparticle albumin-bound paclitaxel, carboplatin, and bevacizumab in first-line patients with advanced nonsquamous non-small cell lung cancer. J Thorac Oncol (2009) 0.99

A Phase III trial of fludarabine, cyclophosphamide, and rituximab vs. pentostatin, cyclophosphamide, and rituximab in B-cell chronic lymphocytic leukemia. Invest New Drugs (2011) 0.98

Dose-adjusting capecitabine minimizes adverse effects while maintaining efficacy: a retrospective review of capecitabine for metastatic breast cancer. Clin Breast Cancer (2011) 0.96

Feasibility assessment of a chemoresponse assay to predict pathologic response in neoadjuvant chemotherapy for breast cancer patients. Anticancer Res (2008) 0.96

An open-label, single-arm, phase 2 trial of panitumumab plus FOLFIRI as second-line therapy in patients with metastatic colorectal cancer. Clin Colorectal Cancer (2011) 0.96

Laparoscopic pyelolithotomy--a technique for the management of stones in the ectopic pelvic kidney. Int J Urol (2004) 0.95

The effect of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial: a meta-analysis of the US, German, Netherlands, and Belgium sub-studies. J Cancer Res Clin Oncol (2010) 0.95

Bone pain associated with once-per-cycle pegfilgrastim is similar to daily filgrastim in patients with breast cancer. Clin Breast Cancer (2003) 0.95